Prostate cancer is the second leading cause of cancer death in the United States. Cancer cells in the prostate depend on androgens for growth and survival. Mitogenic effects of androgens have been linked to their modulation of cell cycle regulatory molecules such as cyclin-dependent kinase 2 and 4 (CDK2 and CDK4). However, the molecular mechanisms for androgen-mediated cell survival are not fully elucidated. We and others have shown that androgens promote prostate cancer survival by antagonizing the function of PTEN, a tumor suppressor protein. Further studies have revealed that androgens block PTEN signaling by directly inhibiting the function of the forkhead transcription factor FOXO1 (FKHR), a key downstream target of PTEN. Our preliminary data demonstrate that CDK2 interacts with and phosphorylates FOXO1 in vitro and in vivo. CDK2 inhibits the function of FOXO1 through phosphorylation of serine 249. Importantly, CDK2- mediated phosphorylation and inhibition of FOXO1 can be reversed upon DNA damage induced by chemotherapeutic agents and irradiation. In view of the roles of androgen-mediated proliferation and survival and the anti-tumor effect of the interaction between androgen ablation and radiation therapy in the clinic, we hypothesize that CDK2-mediated inactivation of FOXO1 plays an important role in androgen-stimulated proliferation, survival, and oxidative stress in prostate cancer cells. To test this hypothesis, we propose to determine (1) whether CDK2-mediated phosphorylation of FOXO1 plays an essential role in androgen- stimulated proliferation and survival of prostate cancer cells;(2) whether androgen-induced phosphorylation of FOXO1 inhibits FOXO1 transcriptional activity in prostate cancer cells;(3) whether activation of FOXO1 is a key factor that mediates the synergistic anti-tumor effect of androgen ablation and radiation therapy. The findings from this work will provide new insights into the working mechanisms of androgen-induced proliferation and survival of prostate cancer cells. Moreover, they should enhance our understanding of the underlying mechanisms of the therapeutic advantage of androgen ablation and radiation therapy in the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA125747-09
Application #
8069244
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2003-08-01
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2013-05-31
Support Year
9
Fiscal Year
2011
Total Cost
$255,475
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
van der Steen, Travis; Tindall, Donald J; Huang, Haojie (2013) Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci 14:14833-59
Stanton, Marissa J; Dutta, Samikshan; Zhang, Heyu et al. (2013) Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res 73:160-71
Wang, Diping; Lu, Ji; Tindall, Donald J (2013) Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. Cancer Lett 335:136-44
Schmidt, Lucy J; Duncan, Kelly; Yadav, Neelu et al. (2012) RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol 26:716-35
Jiang, Jingting; Pan, Yunqian; Regan, Kevin M et al. (2012) Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Prostate 72:225-32
Dehm, Scott M; Tindall, Donald J (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18:R183-96
Nacusi, Lucas P; Tindall, Donald J (2011) Targeting 5?-reductase for prostate cancer prevention and treatment. Nat Rev Urol 8:378-84
Lamont, Kristin R; Tindall, Donald J (2011) Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25:897-907
Huang, Haojie; Tindall, Donald J (2011) Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 1813:1961-4
Heemers, Hannelore V; Schmidt, Lucy J; Sun, Zhifu et al. (2011) Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. Cancer Res 71:1978-88

Showing the most recent 10 out of 23 publications